Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Moderna’s COVID-19 vaccine has received full FDA approval for use in children at higher risk for severe illness.

Moderna reports that it has received full approval from the U.S. Food and Drug Administration for its COVID-19 vaccine, Spikevax.

The latest trading day saw Moderna (MRNA) settling at $33.64, representing a -1.87% change from its previous close.

The FDA has given full approval to Moderna's COVID-19 shot, Spikevax, allowing it to be used in children 6 months to 11 years old, with some limits on who can get it.

Moderna reports that it has received full approval from the U.S. Food and Drug Administration for its COVID-19 vaccine, Spikevax.

Moderna, Inc. (MRNA) on Thursday announced that the U.S. Food and Drug Administration (FDA) has fully approved its COVID-19 vaccine Spikevax in children aged six months through 11 years who are at ...

Moderna Expands Respiratory Vaccine Portfolio with mNEXSPIKE: The FDA recently approved mNEXSPIKE, Moderna’s next-generation COVID-19 vaccine, for older adults and at-risk individuals based on ...

Moderna’s Covid vaccine for children has been given full FDA approval, making it the first such shot for kids in the U.S. that will no longer be administered under an emergency use authorization.